Global Autoimmune Partnering 2014 to 2020 provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
In-depth understanding of Autoimmune deal trends since 2014
Access Autoimmune deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Autoimmune partner companies
Comprehensive access to over 500 links to actual Autoimmune deals entered into by the world's biopharma companies
Indepth review of Autoimmune deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Autoimmune opportunities
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.
The report includes coverage of the following autoimmune diseases: Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Cronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Autoimmune deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Autoimmune deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2014. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.
Companies Mentioned
3M Drug Delivery Systems
3SBio
23andMe
Abarca
AB Biosciences
Abbott Laboratories
Abbvie
Ablynx
Abreos Biosciences
Abzena
Accelerated Cure Project for MS
Accelis Pharma
Accord Healthcare
Aclaris Therapeutics
Acorda Therapeutics
Adacyte Therapeutics
AdAlta
Adare Pharmaceuticals
Adherium
Adocia
Aduro BioTech
Adynxx
Aequus Pharmaceuticals
Aerial BioPharma
Aerpio Therapeutics
Aesthetic Management Partners
Aevi Genomic Medicine
Affibody
Afimmune
AGC Biologics
AIDS Clinical Trials Group
AiVita Biomedical
Akaal Pharma
Akebia Therapeutics
Akorn
Akouos
Akston Biosciences
Alana Healthcare
Alexion Pharmaceuticals
Alfasigma
Alkermes
Allakos
Allegheny Technologies
Allegro Ophthalmics
Allen Institute for Brain Science
Allergan
Allergan (name changed from Actavis)
Alliance for Lupus Research
Alma Bio Therapeutics
Almirall
Alnylam Pharmaceuticals
Alpine Immune Sciences
Altair
AltaVoice
ALTuCELL
Alvine Pharmaceuticals
Alvit LCS Pharma
Alvotech
Alzheimer's Association
Amarex Clinical Research
Amegabiotech
American College of Chest Physicians
American Diabetes Association
American Lung Association
American National Multiple Sclerosis Society
Amgen
AmorChem
AMPEL BioSolutions
Andromeda Biotech
AnGes MG
Angiocrine Bioscience
Anika Therapeutics
ANI Pharmaceuticals
Annette Funicello Research Fund for Neurological Diseases (AFRFND)
Anokion
Anthem Bluecross
Anthera Pharmaceuticals
Antidote
Apexigen
Aphios
Applied Molecular Transport
Aptar Pharma
Aptuit
Aralez Pharmaceuticals
Aratana Therapeutics
Arch Biopartners
Arcutis Biotherapeutics
Arena Pharmaceuticals
argenx
Aristea Therapeutics
Ark Biosciences
Array Biopharma
Arrien Pharmaceuticals
Asana Medical
ASKA Pharmaceuticals
AskAt
Assembly Biosciences
Astellas Pharma
Asthma UK
Astion Pharma
AstraZeneca
Atara Biotherapeutics
Atnahs Pharma
Atopix
Atreca
Aurinia Pharmaceuticals
Auris Medical
Australasian Gastro Intestinal Research Foundation
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards.
"This product, along with our other innovations,...
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...